EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--April 19, 2006--Savient Pharmaceuticals, Inc., (NASDAQ: SVNT - News) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that four abstracts further detailing data on the Phase 2 clinical trial results of its drug development candidate, Puricase® (PEG-uricase), and reporting results of a 12-month non-interventional (observational) study in the Orphan gout population will be presented at the European League Against Rheumatism (EULAR) 2006 Annual Congress in Amsterdam, Netherlands being held June 21-24, 2006.
